SLAMF7 and neoplasm: By augmenting SLAMF7 signals during CD8+ T-cell priming, we were able to induce an effective response to the very low affinity V4 antigen that is about 700-fold less potent than the adequate N4 peptide [52] and towards the tumor-associated self-antigen NY-ESO-1 that is shared among different tumor entities [45].